{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:06:46Z","timestamp":1773871606435,"version":"3.50.1"},"reference-count":49,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Cardiol."],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.2217\/fca-2020-0016","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:31:41Z","timestamp":1590676301000},"page":"361-371","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering"],"prefix":"10.1080","volume":"16","author":[{"given":"Anandita","family":"Agarwala","sequence":"first","affiliation":[{"name":"Division of Cardiology Washington University School of Medicine 660 S. Euclid Campus Box 8086 St Louis\rMO\r63110\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Metabolism & Lipid Research Washington University School of Medicine 660 S. Euclid Campus Box 8127 St Louis\rMO\r63110\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"issue":"139","key":"e_1_3_3_4_1","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"2019","author":"Grundy SM","year":"2018","unstructured":"Grundy SM , StoneNJ, BaileyALet al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019(139), e1082\u2013e1143 (2018).","journal-title":"Circulation"},{"issue":"140","key":"e_1_3_3_5_1","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"2019","author":"Arnett DK","year":"2019","unstructured":"Arnett DK , BlumenthalRS, AlbertMAet al. 2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019(140), e596\u2013e646 (2019).","journal-title":"Circulation"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104413"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2019.16"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M030528"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3340113"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2720181"},{"key":"e_1_3_3_15_1","unstructured":"Highlights of Prescribing Information. (2020). https:\/\/pi.esperion.com\/nexletol\/nexletol-pi.pdf"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M035212"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.310676"},{"key":"e_1_3_3_18_1","unstructured":"A multiple ascending dose study of ETC-1002 in healthy subjects (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01485146"},{"key":"e_1_3_3_19_1","unstructured":"A multiple ascending dose study of ETC-1002 in subjects with mild dyslipidemia (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01105598"},{"key":"e_1_3_3_20_1","unstructured":"Single radiolabeled dose study to investigate the absorption metabolism and excretion of [14C]-ETC-1002 (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02044627"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302677"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.03.003"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.12.025"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.050"},{"key":"e_1_3_3_25_1","unstructured":"A study of the safety pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01779453"},{"key":"e_1_3_3_26_1","unstructured":"Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02178098"},{"key":"e_1_3_3_27_1","unstructured":"Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03193047"},{"key":"e_1_3_3_28_1","unstructured":"Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg ezetimibe 10mg and atorvastatin 20 mg triplet therapy in patients with elevated LDL-C (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03051100"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.05.003"},{"key":"e_1_3_3_30_1","unstructured":"Assessment of the long-term safety and efficacy of bempedoic acid (CLEAR Harmony OLE) (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03067441"},{"key":"e_1_3_3_31_1","unstructured":"Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) in patients with hyperlipidemia and statin intolerant (CLEAR Serenity) (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02988115"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319864671"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803917"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16585"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.05.003"},{"issue":"12268","key":"e_1_3_3_38_1","article-title":"Efficacy of bempedoic acid: a pooled analysis of 4 pivotal Phase III clinical trials","volume":"140","author":"Banach M","year":"2019","unstructured":"Banach M , DuellBP, GottoAet al. Efficacy of bempedoic acid: a pooled analysis of 4 pivotal Phase III clinical trials. Circulation, 140, A12268 (2019).","journal-title":"Circulation"},{"issue":"11417","key":"e_1_3_3_39_1","article-title":"Bempedoic acid and glycemic control: a pooled analysis of 4 Phase III clinical trials","volume":"140","author":"Leiter LA","year":"2019","unstructured":"Leiter LA , BanachM, CatapanoAet al. Bempedoic acid and glycemic control: a pooled analysis of 4 Phase III clinical trials. Circulation, 140, A11417 (2019).","journal-title":"Circulation"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2019.0013"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806747"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319831500"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.07.015"},{"key":"e_1_3_3_44_1","unstructured":"Evaluation of major cardiovascular events in patients with or at high risk for cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406"},{"key":"e_1_3_3_45_1","unstructured":"Esperion completes patient enrollment in the global CLEAR cardiovascular outcomes trial for bempedoic acid. https:\/\/www.esperion.com\/investors-media\/press-releases\/"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16598"},{"key":"e_1_3_3_49_1","unstructured":"Esperion Announces U.S. FDA acceptance of new drug applications (NDAs) for both bempedoic acid and the bempedoic acid\/ezetimibe combination tablet for filing and regulatory review (2019). https:\/\/www.esperion.com\/investors-media\/press releases\/"},{"key":"e_1_3_3_50_1","unstructured":"Esperion announces positive CHMP opinion for the marketing authorisation application for the bempedoic acid \/ ezetimibe fixed dose combination tablet for the treatment of hypercholesterolemia and mixed dyslipidemia (2020). https:\/\/www.esperion.com\/investors-media\/news-releases\/news-release-details\/esperion-announces-us-fda-acceptance-new-drug-applications-ndas\/"},{"key":"e_1_3_3_51_1","unstructured":"Esperion announces positive CHMP opinion for the marketing authorisation application for bempedoic acid for the treatment of hypercholesterolemia and mixed dyslipidemia (2020). https:\/\/www.esperion.com\/investors-media\/news-releases\/news-release-details\/esperion-announces-us-fda-acceptance-new-drug-applications-ndas\/"}],"container-title":["Future Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fca-2020-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:38:58Z","timestamp":1715967538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fca-2020-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.2217\/fca-2020-0016"],"URL":"https:\/\/doi.org\/10.2217\/fca-2020-0016","relation":{},"ISSN":["1479-6678","1744-8298"],"issn-type":[{"value":"1479-6678","type":"print"},{"value":"1744-8298","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}